Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB dis…

This study tests whether combining the targeted drug trastuzumab-deruxtecan with other treatments before surgery is safe and feasible for people with HER2-positive stomach or esophagus cancer that has not spread. About 36 adults will receive the drug combinations before their pla…

This study tests whether a combination of ramucirumab plus FOLFIRI (a standard chemo regimen) works better than ramucirumab plus paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has worsened after one prior chemo treatment. About 429 participan…

This phase 2 trial tests a chemotherapy-light combination of three drugs—rituximab, polatuzumab vedotin, and glofitamab—in 125 patients over 60 with aggressive B-cell lymphoma who cannot tolerate full-dose standard chemo. The goal is to see if this gentler approach can control th…

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This study tests a drug called bemarituzumab combined with different chemotherapies in 126 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). Participants have already tried at least one prior chemotherapy. The goal is to see if…

This study tests whether adding immunotherapy drugs (durvalumab and tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver cancer will …

This study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has a specific FGFR2 gene change. The goal is to see if the combination shrinks tumors. Participants receive bo…